Clinical Trial Update: Trial of Trastuzumab Deruxtecan in Previously Treated HER2 [Phase 2]

View source ↗

Summary

Phase 2 study of trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Yale University | Conditions: Breast Cancer Metastatic | Phase 2 | Status: RECRUITING